iHCK-37 (ASN05260065) is a potent and specific Hck inhibitor with a K i value of 0.22 μM. iHCK-37 blocks HIV-1 viral replication with an EC 50 value of 12.9 μM. iHCK-37 is used for chronic myeloid leukemia (CML) research.

iHCK-37 (5.0-20 μM; 24 hours) exhibits a potent in vitro?antiproliferative activity. The dose (μM) for growth inhibition (GI 50 ) is 5.0-5.8?μM for AML cell lines (HL60, KG1a and U937) and 9.1-19.2?μM for chronic myeloid leukemia cell lines (HEL and K562)[2].iHCK-37 (3-9 μM; plus Erythropoietin) leads to a decrease in ERK, AKT and P70S6K phosphorylation of in lentivirus HCK silenced K562 and U937 cell lines[2].iHCK-37 (3-9 μM) results in a decrease of p-HCK, p-ERK, p-AKT, p-70S6 in the cell line KG1a (AML/CD34 + ), in a dose-dependent manner[2]. Cell Viability Assay[1]Cell Line: U937,?HL60, KG1a, HEL and K562 cells Concentration: 5.0-20 μM Incubation Time: 24 hours Result: Exhibited a reduction of growth in a dose-dependent manner.

516478-09-4

C30H32N4O2S2

544.73

ASN05260065;iHCK-37;iHCK-37

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years